Viking Therapeutics Stock Surges on Acquisition Speculation

Shares of Viking Therapeutics experienced significant upward momentum this week, fueled by renewed takeover speculation and a positive analyst update. The biotech firm’s stock climbed 7.49% to reach $40.60, extending its gains with an additional 4.1% advance in after-hours trading.

Market researchers at Canaccord Genuity reaffirmed their positive stance on Viking Therapeutics, maintaining a “Buy” recommendation while raising their price target. This move highlights the financial community’s continued confidence in the company’s developmental pipeline.

Viking has positioned itself as a key competitor in the rapidly expanding weight-loss medication sector through its GLP-1/GIP candidate VK2735. The growing focus on independent biotech companies follows Pfizer’s successful acquisition of Metsera, Read more...